Please login to the form below

Not currently logged in

BlackThorn Therapeutics appoints CEO

Gregory Vontz joins from Topica Pharmaceuticals

BlackThorn Therapeutics Gregory VontzSan Francisco, US-based biotech BlackThorn Therapeutics has appointed Gregory Vontz as its new chief executive officer.

Vontz brings over 30 years of biotech and pharma industry experience to the role, joining from fungal infection specialist Tropica Pharmaceuticals where he also served as chief executive.

Prior to this, Vontz was president and chief operating officer of Connetics Corporation, spent 12 years in a series of senior marketing and product development roles at Genentech, and worked in sales and sales management at Merck & Co.

Dr Mark Corrigan, chairman of the board at BlackThorn, said: “On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer.

“His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company's mission to develop new treatments for patients suffering from neurobehavioral disorders.”

17th February 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....